Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2729919 | 0.83 | HSD17B10 (0.40) | SMN1; SMN2RECQLHSD17B10HPGDSTS | |
| SCHEMBL25867038 | 0.78 | CHRM2 (0.38) | UCHL1SMN1; SMN2RECQLHSD17B10HPGD | |
| SCHEMBL3302201 | 0.76 | TSHR (0.43) | SMN1; SMN2RECQLHSD17B10HPGDSTS | |
| SCHEMBL599498 | 0.76 | TSHR (0.43) | SMN1; SMN2RECQLHSD17B10HPGDSTS | |
| SCHEMBL14555092 | 0.76 | TSHR (0.43) | SMN1; SMN2RECQLHSD17B10HPGDSTS | |
| SCHEMBL3299171 | 0.76 | TSHR (0.43) | SMN1; SMN2RECQLHSD17B10HPGDSTS | |
| SCHEMBL599499 | 0.76 | TSHR (0.43) | SMN1; SMN2RECQLHSD17B10HPGDSTS | |
| SCHEMBL10163242 | 0.76 | TSHR (0.43) | SMN1; SMN2RECQLHSD17B10HPGDSTS | |
| SCHEMBL3240371 | 0.76 | SMN1; SMN2 (0.41) | SMN1; SMN2RECQLHSD17B10HPGDSTS | |
| SCHEMBL2680322 | 0.75 | SMN1; SMN2 (0.40) | SMN1; SMN2RECQLHSD17B10HPGDSTS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130210804-A1 | TRICYCLIC MGLUR5 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2013-08-15 | — | — | US | disclosed |
| US-20130210804-A1 | TRICYCLIC MGLUR5 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2013-08-15 | — | — | US | disclosed |
| US-20130210804-A1 | TRICYCLIC MGLUR5 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2013-08-15 | — | — | US | disclosed |
| WO-2012061019-A2 | TRICYCLIC MGLUR5 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210804-A1 | TRICYCLIC MGLUR5 RECEPTOR MODULATORS | GRM5, GRM1, GRM2 | UCHL1 3142/4885SMN1; SMN2 1501/4885RECQL 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.